BTT-1023: Phase I data

Top-line data from a double-blind, placebo-controlled, multiple ascending-dose, European Phase I trial in 26 patients showed that up to 8 mg/kg IV BTT-1023 was well tolerated, with 2 BTT-1023-treated patients experiencing a transient exacerbation of their psoriasis symptoms after completing treatment. Several patients treated with BTT-1023 experienced an improvement in their disease as measured by reductions in PASI scores and physicians' clinical assessments compared to no changes in disease activity for any patient receiving placebo. The study consisted of an open-label, single-dose portion in 2 patients, followed by a double-blind portion in 24 patients who received placebo or 1, 2, 4, or 8 mg/kg BTT-1023 for 3 months. ...